Meeting
2018 ASCO Annual Meeting
A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.
Authors
David S. Hong
The University of Texas MD Anderson Cancer Center, Houston, TX
David S. Hong , Drew W. Rasco , Michael H. Veeder , Jason J. Luke , Jason Chandler , Ani Sarkis Balmanoukian , Thomas J. George Jr., Pamela Munster , Jordan Berlin , Martin Gutierrez , Alain C. Mita , Heather A. Wakelee , Selda Samakoglu , Shanhong Guan , Isaiah W. Dimery , Erkut Borazanci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02401048
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2578)
DOI
10.1200/JCO.2018.36.15_suppl.2578
Abstract #
2578
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
First Author: Amin Nassar
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach
Poster
2023 ASCO Annual Meeting
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
First Author: Alissa Jamie Cooper
Poster
2022 ASCO Annual Meeting
Acquired EGFR-resistant mutations in non–small cell lung cancer (NSCLC).
First Author: Luis E. Raez